Menu
Back to User profile » Professor Dave Singh
Papers published by Professor Dave Singh:
Risk of Pneumonia in Patients with COPD Initiating Fixed Dose Inhaled Corticosteroid (ICS) / Long-Acting Bronchodilator (LABD) Formulations Containing Extrafine Beclometasone Dipropionate versus Patients Initiating LABD Without ICS
Price D, Henley W, Cançado JED, Fabbri LM, Kerstjens HA, Papi A, Roche N, Şen E, Singh D, Vogelmeier CF, Nudo E, Carter V, Skinner D, Vella R, Soriano JB, Kots M, Georges G
Pragmatic and Observational Research 2024, 15:1-16
Published Date: 20 January 2024
Airway and Systemic Immune Responses Following the Third COVID-19 Vaccination in COPD Patients
Southworth T, Jackson N, Singh D
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:3027-3036
Published Date: 20 December 2023
Investigation of the Methodology of Specific Airway Resistance Measurements in COPD
Dean J, Singh D
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:2555-2563
Published Date: 13 November 2023
Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis
Singh D, Criner GJ, Agustí A, Bafadhel M, Söderström J, Luporini Saraiva G, Song Y, Licaj I, Jison M, Martin UJ, Psallidas I
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:1595-1599
Published Date: 27 July 2023
The COPD Assessment Test (CAT) and Depression: A Longitudinal Analysis During the COVID-19 Pandemic
Beech A, Singh D
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:1187-1195
Published Date: 13 June 2023
Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS
Bafadhel M, Rabe KF, Martinez FJ, Singh D, Darken P, Jenkins M, Aurivillius M, Patel M, Dorinsky P
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:3061-3073
Published Date: 6 December 2022
New Perspectives on Chronic Obstructive Pulmonary Disease
Celli BR, Singh D, Vogelmeier C, Agusti A
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:2127-2136
Published Date: 6 September 2022
Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial
Gabrio A, Gunsoy NB, Baio G, Martin A, Paly VF, Risebrough N, Halpin DMG, Singh D, Wise RA, Han MK, Martinez FJ, Criner GJ, Martin N, Lipson DA, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:1633-1642
Published Date: 25 July 2022
Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone [Corrigendum]
Price DB, Henley W, Cançado JED, Fabbri LM, Kerstjens HA, Papi A, Roche N, Şen E, Singh D, Vogelmeier CF, Barille S, Nudo E, Carter V, Skinner D, Vella R, Georges G
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:489-490
Published Date: 7 March 2022
CONQUEST: A Quality Improvement Program for Defining and Optimizing Standards of Care for Modifiable High-Risk COPD Patients
Alves L, Pullen R, Hurst JR, Miravitlles M, Carter V, Chen R, Couper A, Dransfield M, Evans A, Hardjojo A, Jones D, Jones R, Kerr M, Kostikas K, Marshall J, Martinez F, Melle MV, Murray R, Muro S, Nordon C, Pollack M, Price C, Sharma A, Singh D, Winders T, Price DB
Patient Related Outcome Measures 2022, 13:53-68
Published Date: 23 February 2022
Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone
Price DB, Henley W, Cançado JED, Fabbri LM, Kerstjens HA, Papi A, Roche N, Şen E, Singh D, Vogelmeier CF, Barille S, Nudo E, Carter V, Skinner D, Vella R, Georges G
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:355-370
Published Date: 15 February 2022
Overcoming Therapeutic Inertia to Reduce the Risk of COPD Exacerbations: Four Action Points for Healthcare Professionals
Singh D, Holmes S, Adams C, Bafadhel M, Hurst JR
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:3009-3016
Published Date: 1 November 2021
CONQUEST Quality Standards: For the Collaboration on Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care
Pullen R, Miravitlles M, Sharma A, Singh D, Martinez F, Hurst JR, Alves L, Dransfield M, Chen R, Muro S, Winders T, Blango C, Muellerova H, Trudo F, Dorinsky P, Alacqua M, Morris T, Carter V, Couper A, Jones R, Kostikas K, Murray R, Price DB
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:2301-2322
Published Date: 12 August 2021
Reply to: “Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies” [Letter]
Barnes NC, Singh D, Lipson DA
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:1299-1301
Published Date: 10 May 2021
The Perception of Physicians on Gender-Specific Differences in the Diagnosis of COPD: Results from a Questionnaire-Based Survey
Raherison-Semjen C, Mezzi K, Kostikas K, Mackay AJ, Singh D
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:901-907
Published Date: 1 April 2021
A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD
Ming SWY, Haughney J, Ryan D, Small I, Lavorini F, Papi A, Singh D, Halpin DMG, Hurst JR, Patel S, Ochel M, Kocks J, Carter V, Hardjojo A, Price DB
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:3093-3103
Published Date: 26 November 2020
Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority Study
Voorham J, Baldi S, Santoro L, Kerkhof M, Contoli M, Fabbri LM, Kerstjens HAM, Luis López-Campos J, Roche N, Singh D, Vogelmeier CF, Price DB
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:2739-2750
Published Date: 29 October 2020
Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD – A Detailed Analysis
Watz H, Rickard K, Rheault T, Bengtsson T, Singh D
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:2199-2206
Published Date: 16 September 2020
An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD
Singh D, D'Urzo AD, Donohue JF, Kerwin EM, Molins E, Chuecos F, Ribera A, Jarreta D
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:2835-2848
Published Date: 6 December 2019
Reproducibility of nasal allergen challenge responses in adults with allergic rhinitis
Pantin CT, Southworth T, Wetzel K, Singh D
Clinical Pharmacology: Advances and Applications 2019, 11:67-76
Published Date: 13 May 2019
Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA
Singh D, Fabbri LM, Vezzoli S, Petruzzelli S, Papi A
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:531-546
Published Date: 28 February 2019
Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT
D'Urzo AD, Singh D, Donohue JF, Kerwin EM, Ribera A, Molins E, Chuecos F, Jarreta D, Garcia Gil E
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:479-491
Published Date: 26 February 2019
When to use single-inhaler triple therapy in COPD: a practical approach for primary care health care professionals
Gaduzo S, McGovern V, Roberts J, Scullion JE, Singh D
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:391-401
Published Date: 13 February 2019
Joint statement for the diagnosis, management, and prevention of chronic obstructive pulmonary disease for Gulf Cooperation Council countries and Middle East-North Africa region, 2017 [Corrigendum]
Mahboub BH, Vats MG, Al Zaabi A, Iqbal MN, Safwat T, Al-Hurish F, Miravitlles M, Singh D, Asad K, Zeineldine S, Al Hajjaj MS
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:115-116
Published Date: 18 January 2019
Effects of baseline symptom burden on treatment response in COPD
Martinez FJ, Abrahams RA, Ferguson GT, Bjermer L, Grönke L, Voß F, Singh D
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:181-194
Published Date: 4 January 2019
The Manchester Respiratory-related Sleep Symptoms scale for patients with COPD: development and validation
Khan N, Vestbo J, Garrow A, Karur P, Kolsum U, Tyson S, Singh D, Yorke J
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:3885-3894
Published Date: 29 November 2018
Feasibility and challenges of using multiple breath washout in COPD
Bell AS, Lawrence PJ, Singh D, Horsley A
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:2113-2119
Published Date: 10 July 2018
Differential anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD pulmonary cells
Higham A, Karur P, Jackson N, Cunoosamy DM, Jansson P, Singh D
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:1279-1288
Published Date: 19 April 2018
The effect of electronic cigarette and tobacco smoke exposure on COPD bronchial epithelial cell inflammatory responses
Higham A, Bostock D, Booth G, Dungwa JV, Singh D
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:989-1000
Published Date: 23 March 2018
The effects of repeated Toll-like receptors 2 and 4 stimulation in COPD alveolar macrophages
Lea SR, Reynolds SL, Kaur M, Simpson KD, Hall SR, Hessel EM, Singh D
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:771-780
Published Date: 2 March 2018
CRTH2 antagonists in asthma: current perspectives
Singh D, Ravi A, Southworth T
Clinical Pharmacology: Advances and Applications 2017, 9:165-173
Published Date: 15 December 2017
The efficacy of extrafine beclomethasone dipropionate–formoterol fumarate in COPD patients who are not "frequent exacerbators": a post hoc analysis of the FORWARD study
Singh D, Vezzoli S, Petruzzelli S, Papi A
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:3263-3271
Published Date: 3 November 2017
Joint statement for the diagnosis, management, and prevention of chronic obstructive pulmonary disease for Gulf Cooperation Council countries and Middle East–North Africa region, 2017
Mahboub BH, Vats MG, Al Zaabi A, Iqbal MN, Safwat T, Al-Hurish F, Miravitlles M, Singh D, Asad K, Zeineldine S, Al-Hajjaj MS
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:2869-2890
Published Date: 9 October 2017
Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide
Singh D, Corradi M, Spinola M, Papi A, Usmani OS, Scuri M, Petruzzelli S, Vestbo J
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:2917-2928
Published Date: 6 October 2017
Perception of symptoms and quality of life – comparison of patients’ and physicians’ views in the COPD MIRROR study
Celli B, Blasi F, Gaga M, Singh D, Vogelmeier C, Pegoraro V, Caputo N, Agusti A
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:2189-2196
Published Date: 27 July 2017
Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study
Singh D, Scuri M, Collarini S, Vezzoli S, Mariotti F, Muraro A, Acerbi D
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:2001-2014
Published Date: 7 July 2017
Clinical characteristics of COPD patients with tidal expiratory flow limitation
Dean J, Kolsum U, Hitchen P, Gupta V, Singh D
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:1503-1506
Published Date: 22 May 2017
Ampicillin resistance in Haemophilus influenzae from COPD patients in the UK
Maddi S, Kolsum U, Jackson S, Barraclough R, Maschera B, Simpson KD, Pascal TG, Durviaux S, Hessel EM, Singh D
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:1507-1518
Published Date: 22 May 2017
LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis
Rodrigo GJ, Price D, Anzueto A, Singh D, Altman P, Bader G, Patalano F, Fogel R, Kostikas K
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:907-922
Published Date: 17 March 2017
Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD
Kardos P, Worsley S, Singh D, Román-Rodríguez M, Newby DE, Müllerová H
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:2885-2895
Published Date: 25 November 2016
Characterization of TLR-induced inflammatory responses in COPD and control lung tissue explants
Pomerenke A, Lea SR, Herrick S, Lindsay MA, Singh D
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:2409-2417
Published Date: 29 September 2016
Neutral sphingomyelinase-2, acid sphingomyelinase, and ceramide levels in COPD patients compared to controls
Lea SR, Metcalfe HJ, Plumb J, Beerli C, Poll C, Singh D, Abbott-Banner KH
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:2139-2147
Published Date: 6 September 2016
Bronchodilator reversibility in patients with COPD revisited: short-term reproducibility
Pascoe S, Wu W, Zhu CQ, Singh D
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:2035-2040
Published Date: 29 August 2016
Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol
Singh D, Maleki-Yazdi MR, Tombs L, Iqbal A, Fahy WA, Naya I
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:1413-1424
Published Date: 24 June 2016
Systematic literature review of patient-reported outcome measures used in assessment and measurement of sleep disorders in chronic obstructive pulmonary disease
Garrow AP, Yorke J, Khan N, Vestbo J, Singh D, Tyson S
International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:293-307
Published Date: 9 February 2015
Inhibition of the early asthmatic response to inhaled allergen by the 5-lipoxygenase activating protein inhibitor GSK2190915: a dose–response study
Singh D, Boyce M, Norris V, Kent SE, Bentley JH
International Journal of General Medicine 2013, 6:897-903
Published Date: 9 December 2013
Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial
Beeh KM, Singh D, Di Scala L, Drollmann A
International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:503-513
Published Date: 31 July 2012
Safety of indacaterol in the treatment of patients with COPD
Donohue JF, Singh D, Kornmann O, Lawrence D, Lassen C, Kramer B
International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:477-492
Published Date: 22 September 2011